Repository logo
 
Publication

Tocilizumab: is there life beyond anti-TNF blockade?

dc.contributor.authorAlves, JD
dc.contributor.authorMarinho, A
dc.contributor.authorSerra, M
dc.date.accessioned2012-04-18T15:24:53Z
dc.date.available2012-04-18T15:24:53Z
dc.date.issued2011
dc.description.abstractAnti-TNF-α therapy has become the most effective biological treatment for rheumatoid arthritis. Despite having changed the prognosis of the disease establishing new targets for treatment strategy, there are several aspects that still remain unmatched. About 30% of the patients with rheumatoid arthritis have a less than satisfactory response to anti-TNF therapy, which has led the way for the pursuit of new targets and approaches to treatment. IL-6 is one of these alternative targets and data from the more recent clinical trials involving tocilizumab (an anti-IL-6 soluble receptor antibody) suggest advantages in relation to some clinical aspects which are not addressed by anti-TNF-α treatment.por
dc.identifier.citationInt J Clin Pract. 2011 Apr;65(4):508-13por
dc.identifier.issn1368-5031
dc.identifier.urihttp://hdl.handle.net/10400.10/557
dc.language.isoengpor
dc.publisherMedicom Internationalpor
dc.subjectRheumatoid arthritispor
dc.subjectArterite reumatóidepor
dc.subjectTocilizumabpor
dc.titleTocilizumab: is there life beyond anti-TNF blockade?por
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceEsher [England]por
oaire.citation.endPage513por
oaire.citation.startPage508por
oaire.citation.titleInternational Journal of Clinical Practicepor
rcaap.rightsrestrictedAccess
rcaap.typearticlepor

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Int J Clin Pract. 2011 Apr, 65(4)508-13.pdf
Size:
92.7 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: